Home › Funds › FULLER & THALER ASSET MANAGEMENT, INC. › HALO

FULLER & THALER ASSET MANAGEMENT, INC. position in HALO

HALOZYME THERAPEUTICS INC · Health Care

FULLER & THALER ASSET MANAGEMENT, INC. reported holding 1,603,065 shares of HALO (HALOZYME THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$177.0M, representing 0.52% of its reported portfolio and ranking #50 among its reported holdings. FULLER & THALER ASSET MANAGEMENT, INC. has disclosed HALO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.60M sh
Reported value held$176.98M
Portfolio Weight0.52%
First reportedQ3 2023
Last changeAdd
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How FULLER & THALER ASSET MANAGEMENT, INC.'s HALO position evolved

FULLER & THALER ASSET MANAGEMENT, INC. first disclosed a stake in HALO in Q3 2023 at 368,394 shares (US$14.1M). The position peaked in Q3 2026 at 1,603,065 shares, worth US$177.0M. Across 13 filings, FULLER & THALER ASSET MANAGEMENT, INC. increased the stake 12 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,603,065 shares valued at US$177.0M — an increase of 112,061 shares quarter over quarter.. Notable position changes include a 39% increase in Q1 2024 (shares rose 29% over the following quarter), a 26% increase in Q2 2024 (shares rose 9% over the following quarter), a 27% increase in Q1 2025 (shares fell 18% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 368.39K $14.07M New
Q4 2023 409.68K $15.14M Add
Q1 2024 568.36K $23.12M Add
Q2 2024 716.57K $37.52M Add
Q3 2024 823.54K $47.14M Add
Q4 2024 887.85K $42.45M Add
Q1 2025 1.13M $72.11M Add
Q2 2025 1.24M $64.66M Add
Q3 2025 1.37M $100.56M Add
Q4 2025 1.38M $92.85M Add
Q1 2026 1.47M $94.70M Add
Q2 2026 1.49M $116.70M Add
Q3 2026 1.60M $176.98M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About HALO and 13F data

HALO (HALOZYME THERAPEUTICS INC) is a Health Care company. 45 other funds we track also report a position in HALO — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$251.9M), SNYDER CAPITAL MANAGEMENT L P (US$187.5M), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (US$178.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding HALO

All HALO fund holders →

FAQ

How long has FULLER & THALER ASSET MANAGEMENT, INC. held HALO?

FULLER & THALER ASSET MANAGEMENT, INC. has disclosed HALO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is FULLER & THALER ASSET MANAGEMENT, INC.'s current position in HALO?

As of Q3 2026, FULLER & THALER ASSET MANAGEMENT, INC. holds 1.60M shares of HALO (HALOZYME THERAPEUTICS INC), valued at $176.98M, representing 0.52% of its reported portfolio and ranking #50.

Has FULLER & THALER ASSET MANAGEMENT, INC. been buying or selling HALO?

In the latest 13F filing (Q3 2026), FULLER & THALER ASSET MANAGEMENT, INC. increased its position in HALO. The position peaked in Q3 2026 at 1.60M shares.

Which other funds hold HALO?

Other major institutional holders of HALO include CONGRESS ASSET MANAGEMENT CO, SNYDER CAPITAL MANAGEMENT L P, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, among 45 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.